Extracellular Vesicles-Mediated Bio-Orthogonal Catalysis in Growing Tumors.

Cells

Instituto de Investigación Sanitaria de Aragón (IIS Aragón), Avda. San Juan Bosco, 13, 50009 Zaragoza, Spain.

Published: April 2024


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Several studies have reported the successful use of bio-orthogonal catalyst nanoparticles (NPs) for cancer therapy. However, the delivery of the catalysts to the target tissues in vivo remains an unsolved challenge. The combination of catalytic NPs with extracellular vesicles (EVs) has been proposed as a promising approach to improve the delivery of therapeutic nanomaterials to the desired organs. In this study, we have developed a nanoscale bio-hybrid vector using a CO-mediated reduction at low temperature to generate ultrathin catalytic Pd nanosheets (PdNSs) as catalysts directly inside cancer-derived EVs. We have also compared their biodistribution with that of PEGylated PdNSs delivered by the EPR effect. Our results indicate that the accumulation of PdNSs in the tumour tissue was significantly higher when they were administered within the EVs compared to the PEGylated PdNSs. Conversely, the amount of Pd found in non-target organs (i.e., liver) was lowered. Once the Pd-based catalytic EVs were accumulated in the tumours, they enabled the activation of a paclitaxel prodrug demonstrating their ability to carry out bio-orthogonal uncaging chemistries in vivo for cancer therapy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11048864PMC
http://dx.doi.org/10.3390/cells13080691DOI Listing

Publication Analysis

Top Keywords

cancer therapy
8
evs compared
8
pegylated pdnss
8
extracellular vesicles-mediated
4
vesicles-mediated bio-orthogonal
4
bio-orthogonal catalysis
4
catalysis growing
4
growing tumors
4
tumors studies
4
studies reported
4

Similar Publications

Impact of Albumin-Binding Moieties on Structure-Affinity-Pharmacokinetic Relationships of Novel FAP-Targeting Radioligands.

Mol Pharm

September 2025

Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29 Yoshida Shimoadachi-cho, Sakyo-Ku, Kyoto 606-8501, Japan.

Fibroblast activation protein (FAP) is an attractive biomarker for tumor-targeting radioligands. While [Ga]Ga-FAPI-46 is a promising FAP-targeting radioligand for cancer diagnosis, clinical application of [Lu]Lu-FAPI-46 for targeted radionuclide therapy is limited due to its insufficient tumor retention. Albumin binder (ALB) including 4-(-iodophenyl)butyric acid is widely utilized to improve tumor accumulation of radioligands.

View Article and Find Full Text PDF

Reality bites: allocating gene therapy for hemoglobinopathies.

Blood Adv

September 2025

Division of Hematology/Oncology, Department of Pediatrics, Baylor College of Medicine, Cancer and Hematology Center, Texas Children's Hospital, Houston, TX.

View Article and Find Full Text PDF

Importance: Patients with advanced cancer frequently receive broad-spectrum antibiotics, but changing use patterns across the end-of-life trajectory remain poorly understood.

Objective: To describe the patterns of broad-spectrum antibiotic use across defined end-of-life intervals in patients with advanced cancer.

Design, Setting, And Participants: This nationwide, population-based, retrospective cohort study used data from the South Korean National Health Insurance Service database to examine broad-spectrum antibiotic use among patients with advanced cancer who died between July 1, 2002, and December 31, 2021.

View Article and Find Full Text PDF

NPY-functionalized niosomes for targeted delivery of margatoxin in breast cancer therapy.

Med Oncol

September 2025

Venom and Biotherapeutics Molecules Laboratory, Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.

Neuropeptide Y (NPY) and the voltage-gated potassium channel Kv1.3 are closely associated with breast cancer progression and apoptosis regulation, respectively. NPY receptors (NPYRs), which are overexpressed in breast tumors, contribute to tumor growth, migration, and angiogenesis.

View Article and Find Full Text PDF